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3300€/QALY for PEG. GUIDE saved 3950€ per patient. Moving
from GUIDE to PEG was associated with an ICER >100,000
EUR/QALY. CONCLUSIONS: Administering combination
therapy with peginterferon alfa-2b and ribavirin in accordance
with the new German guidelines should allow tailoring treatment
efﬁciently to HCV genotype, body weight, and early viral
response in patients with minimal loss of effectiveness. Antiviral
treatment according to the new German guidelines and should
be cost-effective compared to other well-accepted medical 
interventions.
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OBJECTIVES: To assess the efﬁciency of long-term prophylaxis
with oral valganciclovir versus sequential intravenous/oral gan-
ciclovir in the prevention of cytomegalovirus (CMV) infection
and disease in solid organ transplant recipients. METHODS: A
cost minimization analysis was performed from the perspective
of the Spanish National Health System and differential direct
medical costs between both treatments were considered. The efﬁ-
cacy data of valganciclovir regime was obtained from Paya et
al.’s clinical trial (Am J Transplant 2004:611–20). It was con-
ducted a literature review of published clinical trials in order to
obtain the efﬁcacy data of high-risk transplant patients (D+R-)
treated with sequential intravenous/oral ganciclovir. Resource
use, including medication, in the prophylactic treatment with
intravenous/oral ganciclovir were retrieved from published liter-
ature and a retrospective review of 83 clinical charts of kidney,
liver and lung transplant patients in 9 Spanish hospitals. The
resources used with valganciclovir were retrieved from Paya et
al.’s clinical trial. The unit costs of resources were obtained from
national databases (2003€). The results of the study were
expressed in terms of average cost per patient treated with intra-
venous/oral ganciclovir and valganciclovir. RESULTS: At 12
months post-transplantation, the incidence rate of CMV infec-
tion and disease of high risk transplant patients of both long-
term prophylactic regimes were comparable (Kletzmayr J et al.
Transplantation 2000;70:1174–80; Paya et al. 2004). The
average cost of patient treated with valganciclovir and sequen-
tial intravenous/oral ganciclovir was 3295.9€ and 3715.51€,
respectively. The higher overall costs of intravenous/oral ganci-
clovir therapy, compared to oral valganciclovir are due to higher
drug administration costs. CONCLUSIONS: Long-term pro-
phylaxis with oral valganciclovir is a cost-saving option com-
pared to sequential intravenous/oral ganciclovir with similar
efﬁcacy rates, thus the oral therapy is a more efﬁcient strategy
in the prevention of CMV infection and disease in solid organ
transplantation.
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OBJECTIVES: To describe the changes in costs of care for HIV-
positive patients in Italy resulting from the diffusion of new anti-
retroviral combination therapies (HAART). METHODS: In all,
5422 patients from the I.CO.N.A. cohort (Italian Cohort Naive
Antiretrovirals) were followed between 1997 and 2002. This
multi-centric observational study includes adult HIV patients
naïve to antiretroviral therapies. Costs included antiretroviral
therapies (ART), hospital admissions, prophylaxis and treat-
ments for opportunistic infections, and main immuno-virologi-
cal exams. The perspective was that of the National Health
Service. Costs calculated retrospectively and expressed in con-
stant 1997 prices. RESULTS: In the 6-year period considered,
the number of AIDS Deﬁning Events per person-year decreased
from 106 to 26 per thousand, and the number of deaths per
person-year fell from 29 to 8 per thousand. Similarly, hospital-
izations decreased from an annual average of 9.6 days of admis-
sion per patient in 1997 to 0.9 days in 2002. Consequently,
admission costs per person-year decreased from 2.148 euro in
1997 to 256 in 2002, while the average annual costs of ART
increased from 2.145 to 3.149 euro. In only 2 years (from 1997
to 1999), ART costs increased from 42.3% to 85.9% of the total,
while admission costs decreased from 42.3% to 7% and pro-
phylactic treatments from 7.3% to 1.7%. The breakdown of
ART costs shows dual therapies (still widespread at the begin-
ning of the observation period) decreased over time in favor of
HAART, falling from 26.8% in 1997 to 5.9% in 2002. Patients
with fewer than 5 treatment switches had lowest costs distribu-
tions over the entire observation period. CONCLUSIONS: From
1997 to 2002 inpatient costs progressively decreased in favor of
antiretroviral therapy. Annual average costs per patient also
decreased, while total direct costs increased over time: health
resources, ﬁrst concentrated on hospitalized patients were then
distributed over a growing number of subjects.
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OBJECTIVES: When to initiate antiretroviral therapy for
asymptomatic patients remains uncertain. We assessed the costs-
effectiveness of starting highly active antiretroviral therapy
(HAART) at different CD4 cells counts (main predictors of prog-
nosis) as it emerged from Italian clinical practice in recent years.
METHODS: The study considered 3250 HAART-naïve patients
of the I.CO.N.A. cohort (Italian Cohort Naive Antiretrovirals),
enrolled and followed between 1997 and 2002. In correspon-
dence to >= 500, 350–499 and 200–349 CD4 cells/mm3, we
selected immediate and deferred groups accounting for lead time
bias. To assess the effects of early treatment on AIDS-free sur-
vival, we calculated propensity scores to represent the probabil-
ity of early HAART initiation and then estimated separate Cox
models stratiﬁed on propensity score blocks. The average effects
of early vs. deferred treatment on total health costs were
obtained similarly stratifying by propensity score blocks. The
incremental cost-effectiveness ratio (ICER) and the cost-
effectiveness acceptability curve were also derived. RESULTS:
Adjusted for propensity scores there was no difference in the rate
of AIDS/death in those patients who deferred HAART below 500
or 350 CD4 cells/mm3; we found instead a signiﬁcant difference
for immediate HAART at 200–349 CD4 cells/mm3, with a
hazard ratio of 0.32 (95% CI: 0.17–0.61). The average differ-
ence in total costs across propensity score strata was always
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small, although signiﬁcant, and ranged from 2153€ (95% CI:
241–4064) to 2735€ (95% CI: 530–4940) and to 3650€ (95%
CI: 676–6623). At 200–349 CD4 cells/mm3, the ICER was 230€
per AIDS-free month gained and the probability of early treat-
ment being more cost-effective exceeded 0.9 for prices per effec-
tiveness unit greater than 250€. CONCLUSIONS: Although
early HAART initiation does not affect incidence AIDS and
death at high CD4 levels, not deferring HAART below 200 CD4
cells/mm3 proved to be highly cost-effective.
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OBJECTIVES: NAT (Nucleic acid Ampliﬁcation Testing) screen-
ing of blood donations in addition to antibody testing displays
high cost-effectiveness ratios in the developed world. However,
areas with higher prevalence of HIV-infection in developing
countries, such as Ghana, may show more favorable cost-effec-
tiveness ratios for HIV NAT. We evaluated the cost-effectiveness
of MP-NAT (MiniPool-NAT) or SD-NAT (Single
Donation–NAT) in addition to the HIV-antibody screening cur-
rently in place in Ghana from the health care perspective.
METHODS: The residual risk of HIV transmission was derived
from the screening of blood donations to the Ghanaian National
Blood Transfusion Service during 2002. The age, gender, number
of transfusions were registered prospectively in the Korle Bu
teaching hospital (Accra, Ghana) for 193 patients receiving
blood transfusion. Remaining life expectancies of patients receiv-
ing blood transfusion were estimated using WHO gender, age
and country speciﬁc life expectancies. Cost-effectiveness ratios
for MP-NAT and SD-NAT were determined by using a decision
tree model. Health gains were expressed in Disability Adjusted
Life Years (DALY’s). Health gains and costs were discounted by
3%, age correction was not performed. RESULTS: In 2002, the
prevalence of HIV-infection was 3.15% in 18.378 donations.
Unpaid volunteers donated 35% and 65% were replacement
donations by relatives or friends. Average age of the blood trans-
fusion recipients was 23.8 years. On average 0.56 DALY were
averted by MP-NAT and 0.77 by SD-NAT in addition to HIV-
antibody screening. Net costs per DALY averted varied from
US$8868 for MP-NAT to US$13,112 for SD-NAT and was sen-
sitive to test costs. CONCLUSIONS: Adding MP-NAT or SD-
NAT to HIV-antibody screening displays high cost-effectiveness
ratios for Ghana, given the cut-off points for net costs per DALY
averted of US$ 100 to 1000 for developing countries.
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OBJECTIVES: To estimate the value of herd protection in
Switzerland for the seven-valent pneumococcal conjugate
vaccine (PCV-7). METHODS: A cross-sectional pneumococcal
disease health state model was developed examining outcomes
and direct cost savings among Swiss children (ages £10 years)
vaccinated with PCV-7 (assuming a 4-dose schedule and 80%
vaccination coverage) and unvaccinated adults (ages ≥20 years).
Swiss estimates of population size, disease incidence and mor-
tality, and direct medical and non-medical cost were applied to
the model. Vaccine efﬁcacy was assumed to be 97%, 11%, and
6% for invasive pneumococcal disease, pneumococcal pneumo-
nia, and otitis media, respectively. Recently-reported PCV-7-
associated reductions in IPD rates due to herd immunity in the
US were applied to unvaccinated adults 20–39, 40–64, and ≥65
years. RESULTS: PCV-7 vaccination results in 235.5 life years
gained (LYG). Vaccinating each hypothetical annual Swiss cohort
of 80,000 births is expected to save a total of 20,592,499 CHF
(before accounting for vaccine cost), a savings on an additional
598,652 CHF due to herd immunity. As a result of vaccination,
the per-patient payer savings was calculated at 321.76 CHF.
When accounting for herd immunity, PCV-7 has a cost-effec-
tiveness ratio of 19,973 CHF per LYG or 16,607 CHF per QALY;
without herd immunity the cost per LYG and cost per QALY
were 35,378 CHF and 28,822 CHF, respectively. Per-unit
resources required to avoid illness were also lower when bene-
ﬁts of herd immunity are considered. CONCLUSIONS: Wide-
spread PCV-7 use would result in substantial cost savings and
reduction in pneumococcal disease-related morbidity and mor-
tality not only in vaccinated infants, but also in adults. Decreased
nasopharyngeal carriage of S. pneumoniae among those vacci-
nated with PCV-7 is associated with a decline in pneumococcal
disease among unvaccinated community members via reductions
in disease transmission (herd effects).
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OBJECTIVES: Infant vaccination with seven-valent pneumo-
coccal conjugate vaccine (PCV-7) reduces the incidence of pneu-
mococcal diseases, a leading cause of paediatric infections.
METHODS: We built a Markov model simulating lifelong evo-
lution of 538,138 Italian infants receiving or not 4 doses of PCV-
7. The model included 3 states: “<14 years of age”, “>14 years
of age” and “death”. Yearly transitions were allowed. Children
younger than 14 years of age were allowed to incur invasive
pneumococcal diseases (IPD), including meningitis and bacteri-
aemia, otitis, pneumonia and all-cause death. Probability of
pneumococcal infections was age-dependent: in young children
(<4yrs) IPD yearly incidence rate was 59/100,000, while inci-
dence of pneumonia and otitis was 1.1% and 42–82%, respec-
tively. Coverage of vaccine serotypes in IPD was 72%, based on
country-speciﬁc data. Efﬁcacy rates of PCV-7 were provided by
the Kaiser Permanent trial. PCV-7 cost was 39€/dose. Beta dis-
tributions were adopted for incidence rates and gamma distrib-
utions for costs. Life years and costs were discounted at a
3%/year rate. RESULTS: The model calculated that universal
vaccination with PCV-7 would save 215 cases of pneumococcal
meningitis, 17 pneumococcal infection-related deaths and 1251
life years. Vaccination would cost 24,655€ per life year-saved
(95% CI 5281–48,985) in the societal perspective and €47,011
in the NHS perspective (95% CI 35,085–64,732). In the societal
perspective, vaccination costs <20,000€/LYS in 34.8% of the
Monte-Carlo simulations and was cost-saving in areas at high
incidence of IPD (>0.5%/yr) or pneumonia (>4.3%/yr). Univer-
sal vaccination was cost-saving at a vaccine cost lower than
23.5€/dose, in the societal perspective, while no cost-saving
threshold was found in the NHS perspective. The results were
sensitive to the efﬁcacy of PCV-7 in preventing episodes of acute
